MEDIA AVAILABILITY
Inhaled Steroids Best Treatment for
Children with Asthma
| WHAT: |
|
Although several medications are available to help children maintain asthma control, clinical trials directly comparing them have not been conducted. In fact, current recommendations in national and international asthma guidelines are based either on studies of single treatments compared to a placebo in children or on comparison studies in adults.
For the first time, researchers compared the effectiveness and safety of three different asthma medicines for initial daily therapy for school-aged children with mild to moderate persistent asthma: a low dose inhaled corticosteroid (200 mcg fluticasone a day); a combination of a lower dose inhaled corticosteroid and an inhaled long acting beta2 agonist (100 mcg fluticasone each morning plus 50mcg salmeterol twice daily), and a leukotriene receptor antagonist (montelukast). Studying 285 children ages 6 – 14 years, researchers in the Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute (NHLBI) found that after 48 weeks, inhaled corticosteroids are the most effective initial daily therapy for children with mild to moderate persistent asthma. They also found no significant adverse growth effects among any of the medicines studied.
“Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial,” is published in this month's issue of the Journal of Allergy and Clinical Immunology (JACI). These results support the current asthma clinical guidelines, which recommend inhaled corticosteroids as the preferred initial therapy for children with mild to moderate asthma.
The theme of the January issue of the journal is National Institutes of Health asthma networks. The issue features review articles on several NHLBI programs – the Asthma Clinical Research Network, the Childhood Asthma Research and Education Network, the Childhood Asthma Management Program, and the Severe Asthma Research Program – as well as the Asthma and Allergic Diseases Research Centers and the Inner City Asthma Consortium of the National Institute of Allergy and Infectious Diseases (NIAID). |
| WHO: |
|
NHLBI spokespersons are available to comment on the above study as well as on other findings in the journal. NIAID spokespersons are available to comment on the NIAID-funded Asthma and Allergic Diseases Research Centers and the Inner City Asthma Consortium. |
| CONTACT: |
|
To schedule interviews, contact the NHLBI Communications Office at 301-496-4236 or the NIAID News and Public Information Branch at 301-402-1663. |
| RESOURCES: |
|
|
NIAID is a component of the National Institutes of Health. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on basic immunology, transplantation and immune-related disorders, including autoimmune diseases, asthma and allergies.
The National Institutes of Health (NIH)—The Nation's Medical Research Agency—includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov
###
back to top